World News

The new company combines Kincell’s expertise in immune-cell technologies with Cellipont’s experience in stem cells, induced pluripotent stem cells (iPSCs), mesenchymal stromal cells (MSCs), dendritic cells, exosomes and emerging messenger RNA (mRNA) technologies.

The deal builds on a relationship between the companies that began in 2014, including previous transfers of mature medicines from Sanofi to Cheplapharm.

Under the new agreement, Ori will work with its partner to modernise the manufacturing process for an autologous cell therapy.

QurCan will focus on developing and optimising genetic therapeutics using its delivery technology, while Lilly will take responsibility for advancing selected candidates through subsequent development stages.

The partnership complements existing mechanisms for supplying generic versions of lenacapavir and aims to address gaps in HIV prevention across the region.

It builds on an earlier MoU signed by the two organisations in 2022 and sets out areas for deeper collaboration on health system strengthening and emerging health challenges.

Developed by Curium, Bexlutry is a lutetium-177 dotatate injection that references Novartis’ Lutathera, which is approved to treat gastroenteropancreatic neuroendocrine tumors (GEP NETs).

GSK will take full global rights to the experimental TCE programme in return for an upfront payment and potential development and commercial milestone payments.

Chile reported its last human case of dog transmitted rabies in 1972.

WHO leaders will also meet with heads of state and government, health ministers, development banks, multilateral organisations, philanthropic foundations, civil society groups and scientific institutions.